Back
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.
Journal article

Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.

  • Garcia-Garcia HM Cardialysis, Rotterdam, The Netherlands (H.M.G.-G., Y.O., M.-a.M., G.A.v.E.). eugene.mcfadden@hse.ie hect2701@gmail.com patrick.w.j.c.serruys@gmail.com.
  • McFadden EP Interventional Cardiology, Cork University Hospital, Ireland (E.P.M.). eugene.mcfadden@hse.ie hect2701@gmail.com patrick.w.j.c.serruys@gmail.com.
  • Farb A US Food and Drug Administration, Washington, DC (A.F., B.Z.).
  • Mehran R Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (R.M.).
  • Stone GW Clinical Trials Center, Cardiovascular Research Foundation and Division of Cardiology, Columbia University Medical Center, New York, NY (G.W.S.).
  • Spertus J Mid America Heart Institute, University of Missouri, Kansas City (J.S.).
  • Onuma Y Cardialysis, Rotterdam, The Netherlands (H.M.G.-G., Y.O., M.-a.M., G.A.v.E.).
  • Morel MA Cardialysis, Rotterdam, The Netherlands (H.M.G.-G., Y.O., M.-a.M., G.A.v.E.).
  • van Es GA Cardialysis, Rotterdam, The Netherlands (H.M.G.-G., Y.O., M.-a.M., G.A.v.E.).
  • Zuckerman B US Food and Drug Administration, Washington, DC (A.F., B.Z.).
  • Fearon WF Stanford University Medical Center, CA (W.F.F.).
  • Taggart D Nuffield Department of Surgery, University of Oxford, United Kingdom (D.T.).
  • Kappetein AP Department of Cardiothoracic Surgery, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands (A.-P.R.).
  • Krucoff MW Duke University Medical Center/Duke Clinical Research Institute, Durham, NC (M.W.K.).
  • Vranckx P Hartcentrum Hasselt and Faculty of Medicine and Life Sciences University of Hasselt, Belgium (P.V.).
  • Windecker S Bern University Hospital, Switzerland (S.W.).
  • Cutlip D Harvard Clinical Research Institute, Boston, MA (D.C.).
  • Serruys PW Centre for International Cardiovascular Health, Imperial College London, United Kingdom (P.W.S.) eugene.mcfadden@hse.ie hect2701@gmail.com patrick.w.j.c.serruys@gmail.com.
Show more…
  • 2018-06-13
Published in:
  • Circulation. - 2018
controlled clinical trials
myocardial infarction
revascularization
scaffold
stents
Aortic Valve Stenosis
Bioprosthesis
Blood Vessel Prosthesis
Blood Vessel Prosthesis Implantation
Clinical Trials as Topic
Consensus
Coronary Vessels
Humans
Prosthesis Design
Stents
English The Academic Research Consortium (ARC)-2 initiative revisited the clinical and angiographic end point definitions in coronary device trials, proposed in 2007, to make them more suitable for use in clinical trials that include increasingly complex lesion and patient populations and incorporate novel devices such as bioresorbable vascular scaffolds. In addition, recommendations for the incorporation of patient-related outcomes in clinical trials are proposed. Academic Research Consortium-2 is a collaborative effort between academic research organizations in the United States and Europe, device manufacturers, and European, US, and Asian regulatory bodies. Several in-person meetings were held to discuss the changes that have occurred in the device landscape and in clinical trials and regulatory pathways in the last decade. The consensus-based end point definitions in this document are endorsed by the stakeholders of this document and strongly advocated for clinical trial purposes. This Academic Research Consortium-2 document provides further standardization of end point definitions for coronary device trials, incorporating advances in technology and knowledge. Their use will aid interpretation of trial outcomes and comparison among studies, thus facilitating the evaluation of the safety and effectiveness of these devices.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/43984
Statistics
Document views: 16 File downloads: